Baxalta (Baxalta) Buyback Yield % : 0.00 (As of May. 06, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Baxalta Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Baxalta's current buyback yield was 0.00%.

Baxalta Buyback Yield % Historical Data

The historical data trend for Baxalta's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baxalta Buyback Yield % Chart

Baxalta Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Buyback Yield %

Baxalta Quarterly Data
	Dec12	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16
Buyback Yield %	Get a 7-Day Free Trial						-	-	-	-	-

Competitive Comparison of Baxalta's Buyback Yield %

For the Biotechnology subindustry, Baxalta's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Baxalta's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Baxalta's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Baxalta's Buyback Yield % falls into.

Baxalta Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Baxalta's Buyback Yield for the fiscal year that ended in Dec. 2015 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	0)	/	26512.57161
	=	0.00%

Baxalta's annualized Buyback Yield for the quarter that ended in Mar. 2016 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0)	*	4	/	27584.11
	=	0.00%

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Mar. 2016) data.

Baxalta Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Baxalta's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Baxalta (Baxalta) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baxalta Inc (NYSE:BXLT) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.baxalta.com

Baxalta Inc was incorporated on September 8, 2016. It is a biopharmaceutical company engaged in the field of unmet medical needs covering various diseases which includes haemophilia, immunology and oncology. The Company develops, manufactures and markets a diverse portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia. It also invests in emerging technology platforms, including gene therapy and biosimilars. Its competitors include Advate, Feiba, Gammagard. The Company is subject to rules and regulations put forth by the jurisdiction it operates in.

Executives

Gail D Fosler	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
John Glasspool	officer: See Remarks	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Dagmar Rosa-bjorkeson	officer: EVP and President, Biosimilars	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
David D. Meek	officer: EVP and President, Oncology	3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Karen Jean Ferrante	director	150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Peter G Edwards	officer: SVP and General Counsel	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Robert J. Hombach	officer: EVP. CFO and COO	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Blake E Devitt	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Wayne T Hockmeyer	director	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anne-marie Law	officer: EVP & Head of Human Resources	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Stroucken Albert P L	director	BAXTER INTERNATIONAL INC., ONE BAXTER PARKWAY, DEERFIELD IL 60015
Gavin James R Iii	director	BAXTER INTERNATIONAL INC, ONE BAXTER PARKWAY, DEERFIELD IL 60015
John D Forsyth	director	C/O BAXTER INTERNATIONAL, ONE BAXTER PARKWAY, DEERFIELD IL 60015
Ludwig Hantson	director, officer: President and CEO	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Francois Nader	director	550 HILLS DRIVE, BEDMINSTER NJ 07921